Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Inventory (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Inventory data on record, last reported at $301050.0 in Q1 2025.

  • For Q1 2025, Inventory fell 62.13% year-over-year to $301050.0; the TTM value through Mar 2025 reached $301050.0, down 62.13%, while the annual FY2025 figure was $301050.0, 62.13% down from the prior year.
  • Inventory reached $301050.0 in Q1 2025 per SXTC's latest filing, down from $794855.0 in the prior quarter.
  • Across five years, Inventory topped out at $859696.0 in Q1 2021 and bottomed at $50313.0 in Q1 2022.
  • Average Inventory over 5 years is $507433.6, with a median of $531254.0 recorded in 2023.
  • Peak YoY movement for Inventory: crashed 94.15% in 2022, then soared 955.9% in 2023.
  • A 5-year view of Inventory shows it stood at $859696.0 in 2021, then plummeted by 94.15% to $50313.0 in 2022, then skyrocketed by 955.9% to $531254.0 in 2023, then soared by 49.62% to $794855.0 in 2024, then crashed by 62.13% to $301050.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $301050.0 in Q1 2025, $794855.0 in Q1 2024, and $531254.0 in Q1 2023.